Statins and stroke: Beyond the reduction in cholesterol;Ictus y estatinas: Más allá de la reducción de los valores de colesterol

Clinica e Investigacion en Arteriosclerosis

Volumn 20, Issue 6, 2008, Pages 239-246

  Castilla Guerra, Luis ^a   Hernández, María Dolores Jiménez ^b   Moreno, María Del Carmen Fernández ^c  

^a HOSPITAL DE LA MERCED   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

Cerebrovascular disease; Statins; Stroke prevention

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

ADJUVANT THERAPY; ANGIOPLASTY; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG MECHANISM; FIBRINOLYSIS; HEART PROTECTION; HUMAN; INCIDENCE; MEDLINE; META ANALYSIS; RECURRENT DISEASE; REVIEW; RISK FACTOR; SECONDARY PREVENTION; STROKE; SYSTEMATIC REVIEW;

EID: 58449104824     PISSN: 02149168     EISSN: 15781879     Source Type: Journal    
DOI: 10.1016/S0214-9168(08)75785-1     Document Type: Article

References (42)

1. Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of colesterol-lowering treatment: prospective meta-analysis of data from 90.056 participants in 14 randomised trilas of statins. Lancet. 2005;366:1267-78.
2. Kearney PM, Baigent C. Statins: are any questions unanswered? Curr Opin Lipidol. 2006;17:418-25.
3. Castilla-Guerra L, Fernández-Moreno MC, López-Chozas JM, Jiménez-Hernández MD. Estatinas y enfermedad cerebrovascular: nuevas perspectivas en la prevención del ictus. Rev Neurol. 2007;44:95-100.
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.
5. Byington RP, Davis BR, Plehn JF, White HD, Baker J, Cobbe SM, et al; for the PPP Investigators. The Prospective Pravastatin Pooling (PPP) Project. Circulation. 2001;103:387-92.
6. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13.000 strokes in 450.000 people in 45 prospective cohorts. Lancet. 1995;346:1647-53.
7. Vivancos-Mora J, Gil-Núñez AC. Lipids and stroke: the opportunity of lipid-lowering treatment. Cerebrovasc Dis. 2005;20 Suppl 2:53-67.
8. Horenstein RB, Smith DE, Mosca L. Cholesterol predicts stroke mortality in the Women's Pooling Project. Stroke. 2002;33:1863-8.
9. Kurth T, Everett BM, Buring JE, Kase CS, Ridker PM, Gaziano JM. Lipid levels and the risk of ischemic stroke in women. Neurology. 2007;68:556-62.
10. Amarenco P, Labreuche J, Lavallée PH, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis. Stroke. 2004;35:2902-9.
11. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques. Implications for plaque stabilization. Circulation. 2001;103:926-33.
12. Di Napoli P, Taccardi AA, Oliver M, De Caterina R. Statins and stroke: evidence for cholesterol-independent effects. Eur Heart J. 2002;23:1908-21.
13. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89-118.
14. Mercuri M, Bond MG, Sirtori CR, Crepaldi G, Feruglio FS, Descovich G, et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med. 1996;101:627-34.
15. Smilde TJ, Van Wissn S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001;357:577-81.
16. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 2002;106:2055-60.
17. Reid JA, Wolsley C, Lau LL, Hannon RJ, Lee B, Young IS, et al. The effect of pravastatin on intima media thickness of the carotid artery in patients with normal cholesterol. Eur J Vasc Endovasc Surg. 2005;30:464-8.
18. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals. A randomised placebo-control trial. Lancet. 2002;360:7-22.
19. Kennedy J, Quan H, Buchan AM, Ghali WA, Feasby TE. Statins are associated with better outcomes after carotid endarterectomy in symptomatic patients. Stroke. 2005;36:2058-9.
20. Casani L, Sánchez-Gómez S, Vilahur G, Badimon L. Pravastatin reduces thrombogenicity by mechanisms beyond plasma cholesterol lowering. Thomb Haemost. 2005;94:1035-41.
21. Waters DD, Schwartz GG, Olsson AG, Zeiher A, Oliver MF, Ganz P, et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation. 2002;106:1690-5.
22. Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parplagia PP, et al. Effect of the HMG-CoA reductase inhibitors on the blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension. 1999;34:1281-6.
23. Stepien K, Tomaszewski M, Czuczwar SJ. Neuroprotective properties of statins. Pharmacol Rep. 2005;57:561-9.
24. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-35.
25. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-7.
26. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-22.
27. Castilla-Guerra L, Fernández-Moreno MC, Jiménez- Hernández MD, López-Chozas JM. Statins and stroke. What an internist should know. Eur J Intern Med. 2008;19:8-14.
28. Sever PS, Dahof B, Poulter NR, Wedel H, Beevers G, Caufield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-58.
29. Colhoun HM, Betteridge DJ, Durrington PN, Neil HA, Livinstone SJ, Thomason MJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-96.
30. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke. 2006;37:1583-633.
31. Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici H, Rudolf AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. N Engl J Med. 2006;355:549-59.
32. Ovbiagele B, Kidwell CS, Saver JL. Expanding indications for statins in cerebral ischemia. Arch Neurol. 2005;62:67-72.
33. Hankey GJ. Statins after transient ischaemic attack and ischaemic stroke. Lancet Neurol. 2006;5:810-2.
34. Castilla-Guerra L, Fernández-Moreno MC, Jiménez- Hernández MD. Estatinas tras un ictus o AIT. ¿Café para todos? Med Clin (Barc). 2007;128:559.
35. Vergouwen MDI, De Haan RJ, Vermeulen M, Roos Y. Statins treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke. 2008;39:497-502.
36. Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE, Callahan A 3rd, et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2007;38:3198-204.
37. Chen J, Zhang ZG, Li Y, Wang Y, Wang L, Jiang H, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol. 2003;53:743-51.
38. Gertz K, Laufs U, Lindauer U, Nickenig G, Bohm M, Dirnagl U, et al. Withdrawal of statins treatment abrogates stroke protection in mice. Stroke. 2003;34:551-7.
39. Jonsson N, Asplund K. Does pretreatment with statins improve clinical outcome after stroke? A pilot case-referent study. Stroke. 2001;32:1112-5.
40. Álvarez-Sabin J, Huertas R, Quintana M, Ribera M, Delgado P, Ribó M, et al. Prior statin use may be associated with improved stroke outcome after tissue plasminogen activator. Stroke. 2007;38:1076-8.
41. Montaner J, Chacón P, Krupinski J, Rubio F, Millán M, Escudero D, et al. Safety and efficacy of statin in acute phase of ischemic stroke: the MISTICS Trial. Stroke. 2004;35:293.
42. Prinz V, Lauf V, Gertz K, Kronemberg G, Balkaya M, Leithner C, et al. Intravenous rosuvastatin for acute stroke treatment. An animal study. Stroke. 2008;39:433-8.